1. A multicenter, single-arm, phase II clinical trial of adrenomedullin in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
- Author
-
Kazuo Washida, Satoshi Saito, Tomotaka Tanaka, Yuriko Nakaoku, Hiroyuki Ishiyama, Soichiro Abe, Takehito Kuroda, Shinsaku Nakazawa, Chikage Kakuta, Katsuhiro Omae, Kenta Tanaka, Manabu Minami, Yoshiaki Morita, Tetsuya Fukuda, Akihiro Shindo, Takakuni Maki, Kazuo Kitamura, Hidekazu Tomimoto, Toshihiko Aso, and Masafumi Ihara
- Subjects
Adrenomedullin ,Arterial spin labeling ,Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy ,Cerebral blood flow ,Clinical trial ,Specialties of internal medicine ,RC581-951 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of hereditary cerebral small vessel disease (SVD), currently lacks disease-modifying treatments. Adrenomedullin (AM), a vasoactive peptide with angiogenic, vasodilatory, anti-inflammatory, and anti-oxidative properties, shows potential effects on the neuro-glial-vascular unit. Objective: The AdrenoMedullin for CADASIL (AMCAD) study aims to assess the efficacy and safety of AM in patients with CADASIL. Sample size: Overall, 60 patients will be recruited. Methods: The AMCAD is a multicenter, investigator-initiated, single-arm phase II trial. Patients with a confirmed CADASIL diagnosis, based on NOTCH3 genetic testing, will receive an 8-h AM treatment (15 ng/kg/min) for 14 days following a baseline assessment (from day 1 to day 14). Follow-up evaluations will be performed on days 15, 28, 90, and 180. Study outcomes: The primary endpoint is the cerebral blood flow change rate in the frontal cortex, evaluated using arterial spin labeling magnetic resonance imaging, from baseline to day 28. Summary statistics, 95% confidence intervals, and a one-sample t-test will be used for analysis. Conclusion: The AMCAD study aims to represent the therapeutic potential of AM in patients with CADASIL, addressing an unmet medical need in this challenging condition. Clinical Trial Registration: jRCT 2,051,210,117 (https://jrct.niph.go.jp/en-latest-detail/jRCT2051210117).
- Published
- 2024
- Full Text
- View/download PDF